On September 15, 2022 ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics, reported that Dan MacLeod, Ph.D., the company’s vice president of discovery, will present at the 7th Annual CAR-TCR Summit taking place September 19-22, 2022 in Boston (Press release, immunoSCAPE, SEP 15, 2022, View Source [SID1234619593]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The CAR TCR Summit is a multi-day, industry leading comprehensive forum that explores discovery through to commercialization to deliver safe, effective, and commercially viable CAR and TCR therapies.
At the summit, Dr. MacLeod will participate in several sessions:
Discovery of TCRs Targeting Novel Antigens Using Deep Immunomics
Wednesday, September 21 at 11:30am ET
Discovery Track: Accelerating Target Identification & Validation – Morning Session
Discussion Points:
Discovery and development of novel TCR-based therapeutics using the Deep Immunomics platform
Identification of therapeutically relevant TCRs against both well characterized and novel targets across multiple HLA types
Applying computational approaches to advance TCR Discovery for novel targets
Panel Discussion: Driving Target Discovery with Novel AI Technology
Wednesday, September 21 at 3:00pm ET
Panel Discussion: Accelerating Target Identification & Validation – Post-Lunch Session
Panelists: Dan MacLeod, ImmunoScape; Ely Porter, Rootpath; Luke Pase, Anocca
Discussion Points:
How to advance the discovery of new epitope targets for solid tumors using innovative high-throughput screening and computational AI techniques
How can we better leverage bioinformatic platforms to advance drug discovery?
ImmunoScape’s differentiated Deep Immunomics platform utilizes the company’s proprietary combinatorial barcoding technology to enable the discovery and in-depth characterization of rare cancer-specific T-cells at high resolution. ImmunoScape’s platform is able to simultaneously evaluate tens of millions of T-cells in blood samples from hundreds of cancer patients to identify clinically relevant T-cell clones. The corresponding T-cell receptors (TCRs) are currently being evaluated and prioritized to form a diverse pipeline of TCR-T-cell therapies covering multiple antigens and HLA restrictions.
To see the full summit schedule, and to register for the event, please visit https://car-tcr-summit.com/.
To set up a time to meet with Dr. MacLeod or ImmunoScape CEO Choon-Peng Ng at the summit, please email [email protected].
To learn more about ImmunoScape, please visit View Source